OKYO PHARMA LTD
OKYONASDAQTrading Snapshot
- Day Range
- $1.49 – $1.51
- 52-Week Range
- —
- Volume
- $3.26B
- Avg Volume
- $4.20B
- Shares Outstanding
- 52.5M
- Next Earnings
- Sep 12, 2026
Fundamentals Snapshot
- Annual Revenue
- $6M
- Last Q Revenue
- $2M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own OKYO
- ✓High-growth profile — revenue up +42.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 55% gross margin and 10% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About OKYO PHARMA LTD
OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer
LONDON and NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that Raj Patil, PhD, Chief Scientific Officer of OKYO Pharma has increased his holdings with the purchase of 3,363 of the Company’s ordinary shares on NASDAQ at $1.49 per share, bringing his total holding to 20,030 ordinary sh
OKYO Pharma Says Chief Scientific Officer Raj Patil Purchases Of 3,363 Of Ordinary Shares On NASDAQ At $1.49 Per Share
OKYO Pharma Limited (NASDAQ:OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced
OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026
LONDON and NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced its participation in the BTIG Biotechnology Conference 2026 taking place virtually on July 28-29, 2026. Company Participation: Robert J. Dempsey, Chief Executive Officer, Keeren Shah, Chief Financial Officer, Flavio Mantelli M
OKYO Pharma Announces Purchase of Shares by Director
LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that OKYO Pharma’s Non-Executive Director, John Brancaccio has purchased 5,000 of the Company’s ordinary shares on NASDAQ at $1.48 per share, bringing his total holding to 35,201 shares. About OKYO Pharma OKYO Pharma Limited (
OKYO Pharma Announces Purchase of Shares by Chief Executive Officer
LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that OKYO Pharma’s Chief Executive Officer, Robert J. Dempsey, has purchased 15,000 of the Company’s ordinary shares on NASDAQ at $1.54 per share. About OKYO Pharma OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopha
OKYO Pharma Says CEO Robert Dempsey Purchases 15,000 Of Its Ordinary Shares On NASDAQ At $1.54 Per Share
OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced